Dr. Lutwyche is the Chief Executive Officer and President of Genevant Sciences Corporation. Previously, he was Chief Technology Officer and Vancouver Site Head for Genevant. Prior to joining Genevant, Peter was Chief Technology Officer of Arbutus Biopharma, where he led the development of the company’s nucleic acid-delivery technology. Before his experience at Arbutus, he was Head of Pharmaceutical Development at QLT, where he contributed to the development and commercialization of VISUDYNE®. Peter has over 20 years of experience in the field of nucleic acid-based products. Dr. Lutwyche holds a PhD in chemistry from the University of British Columbia and a BSc in chemistry from the University of Warwick.